Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
在两项 3 期临床试验中,基因表达和蛋白质组学分析表明,使用阿尼弗鲁单抗阻断 I 型干扰素可调节系统性红斑狼疮患者的关键免疫病理通路。
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-225445
Baker, Tina; Sharifian, Hoda; Newcombe, Paul J; Gavin, Patrick G; Lazarus, Mark N; Ramaswamy, Madhu; White, Wendy I; Ferrari, Nicola; Muthas, Daniel; Tummala, Raj; Morand, Eric F; Furie, Richard A; Vital, Edward M; Chamberlain, Chris; Platt, Adam; Al-Mossawi, Hussein; Brohawn, Philip Z; Csomor, Eszter